PMC:7497282 / 35489-36750 JSONTXT

{"project":"MyTest","denotations":[{"id":"32741232-21029809-29927025","span":{"begin":366,"end":368},"obj":"21029809"},{"id":"32741232-21029809-29927026","span":{"begin":479,"end":481},"obj":"21029809"},{"id":"32741232-22298920-29927027","span":{"begin":964,"end":966},"obj":"22298920"},{"id":"32741232-22459121-29927028","span":{"begin":1097,"end":1099},"obj":"22459121"},{"id":"32741232-8610692-29927029","span":{"begin":1134,"end":1137},"obj":"8610692"},{"id":"32741232-8610692-29927030","span":{"begin":1251,"end":1254},"obj":"8610692"},{"id":"32741232-7795316-29927030","span":{"begin":1251,"end":1254},"obj":"7795316"}],"namespaces":[{"prefix":"_base","uri":"https://www.uniprot.org/uniprot/testbase"},{"prefix":"UniProtKB","uri":"https://www.uniprot.org/uniprot/"},{"prefix":"uniprot","uri":"https://www.uniprot.org/uniprotkb/"}],"text":"In 2010, KRI performed an economic analysis that estimated 40-50 billion US$2013 in net benefits for the GPEI for 1988-2035. The range of estimates depended on whether successfully coordinated OPV cessation following WPV eradication included global use of IPV or not (with the lower end of the range of net benefits (i.e. less desirable) reflecting the use of IPV) [25]. That analysis assumed successful WPV eradication in 2012 and considered the impacts of a delay out to 2015 [25]. KRI contributed to discussions about the role of economic analyses in the evaluation of global disease management efforts [195] and the development of eradication investment cases [196], in book chapters not captured by the systematic review. In 2012, KRI explored trends in the risks of poliovirus transmission in the US and recognized that imported live polioviruses could potentially circulate in a population with high IPV coverage, although the risks in the US appeared low [26]. KRI also explored the probability of undetected wild poliovirus circulation after apparent global interruption of transmission [27] (by extending a simple SC model [197] developed and applied in the mid-1990s to support certification of elimination of polioviruses in the Americas [197–199])."}

{"project":"2_test","denotations":[{"id":"32741232-21029809-29927025","span":{"begin":366,"end":368},"obj":"21029809"},{"id":"32741232-21029809-29927026","span":{"begin":479,"end":481},"obj":"21029809"},{"id":"32741232-22298920-29927027","span":{"begin":964,"end":966},"obj":"22298920"},{"id":"32741232-22459121-29927028","span":{"begin":1097,"end":1099},"obj":"22459121"},{"id":"32741232-8610692-29927029","span":{"begin":1134,"end":1137},"obj":"8610692"},{"id":"32741232-8610692-29927030","span":{"begin":1251,"end":1254},"obj":"8610692"},{"id":"32741232-7795316-29927030","span":{"begin":1251,"end":1254},"obj":"7795316"}],"text":"In 2010, KRI performed an economic analysis that estimated 40-50 billion US$2013 in net benefits for the GPEI for 1988-2035. The range of estimates depended on whether successfully coordinated OPV cessation following WPV eradication included global use of IPV or not (with the lower end of the range of net benefits (i.e. less desirable) reflecting the use of IPV) [25]. That analysis assumed successful WPV eradication in 2012 and considered the impacts of a delay out to 2015 [25]. KRI contributed to discussions about the role of economic analyses in the evaluation of global disease management efforts [195] and the development of eradication investment cases [196], in book chapters not captured by the systematic review. In 2012, KRI explored trends in the risks of poliovirus transmission in the US and recognized that imported live polioviruses could potentially circulate in a population with high IPV coverage, although the risks in the US appeared low [26]. KRI also explored the probability of undetected wild poliovirus circulation after apparent global interruption of transmission [27] (by extending a simple SC model [197] developed and applied in the mid-1990s to support certification of elimination of polioviruses in the Americas [197–199])."}